Prelude Therapeutics (PRLD) Other Accumulated Expenses (2019 - 2026)

Prelude Therapeutics has reported Other Accumulated Expenses for 8 years, with the latest figure at $911000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses rose 30.89% year-over-year to $911000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $911000.0 (up 30.89% YoY) and the FY2025 annual result came in at $965000.0, up 25.16% from the prior year.
• Other Accumulated Expenses eased to $911000.0 in Q1 2026 per PRLD's latest filing, from $965000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $965000.0 in Q4 2025 and troughed at $175000.0 in Q3 2022.
• A 5-year average of $707411.8 and a median of $801000.0 in 2024 frame the typical range for Other Accumulated Expenses.
• The widest YoY moves for Other Accumulated Expenses: up 1164.29% in 2022, down 69.3% in 2022.
• Over 5 years, Other Accumulated Expenses stood at $524000.0 in 2022, then soared by 80.34% to $945000.0 in 2023, then fell by 18.41% to $771000.0 in 2024, then grew by 25.16% to $965000.0 in 2025, then slipped by 5.6% to $911000.0 in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $911000.0, $965000.0, and $963000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.